



DKA in Focus: What the New Consensus Means for Practice

ACC. Prevalence And Clinical Impact Of Hypercortisolism In Individuals With Resistant Hypertension: Primary Results From The Momentum Study. Available at: <https://accscientificsession.acc.org/Plan-Your-Program/Education-Sessions/Late-Breakers>. Accessed March 1, 2026.

Bancos I, Geer EB, Castinetti F, et al. 7790 A Non-interventional, Multinational, Phase IV Study to Evaluate the Long-Term Safety and Efficacy of Osilodrostat in Patients with Endogenous Cushing's Syndrome (LINC 6): 1-Year Real-World Interim Analysis. *J Endocr Soc.* 2024;8(Supplement_1):1098.

Bancos I, Castinetti F, Geer EB, et al. SUN-054 Long-Term, Real-World, Safety and Effectiveness of Osilodrostat In Patients With Pituitary and Non-Pituitary Cushing's Syndrome: 2-Year Interim Data From LINC 6. *J Endocr Soc.* 2025;9(Suppl 1):1639.

ClinicalTrials.gov. Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS). Available at: <https://clinicaltrials.gov/study/NCT07104812>. Accessed March 1, 2026.

Dobri GA, Arnaldi G, Auchus R, et al. MON-088 Effects Of Relacorilant On Pituitary Tumor Volume In Patients With Cushing Disease: Results From The Phase 3 Grace Study. *J Endocr Soc.* 2025;9(Supplement_1):1419.

Elenius H, McGlotten R, Moore C, et al. 9330 Atumelnant (crn04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With Acth-Dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-Label Study. *J Endocr Soc.* 2024;8(Suppl 1):114.

Fleseriu M, Badiu CP, Bancos I, et al. OR12-04 Clotriben, an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, vs Placebo in a Phase II Trial for ACTH-dependent Cushing's Syndrome (RESCUE). *J Endocr Soc.* 2025;9(Suppl 1):1471.

Hamrahian A, Aresta C, Badiu C, et al. Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study. Presented at the American Association of Clinical Endocrinologists 2025 Annual Meeting. Orlando, FL.

Jabbour S, Arnaldi G, Auchus R, et al. Relacorilant on Blood Pressure and Antihypertensive Medication Burden in Patients With Hypercortisolism and Hypertension: Results From the GRACE Study. Poster Presented at Heart in Diabetes June 6-8, 2025. Abstract 0097.

Pivonello R, Arnaldi G, Auchus R, et al. Medical treatment of hypercortisolism with relacorilant: Final results of the phase 3 GRACE study. *Endocrine Abstracts.* 2025;110:P69.